Recent Finacing
Recent Raise
Integra Therapeutics develops FiCAT, a gene‑writing platform combining CRISPR‑Cas accuracy with engineered piggyBac transposase for ex vivo T‑cell and HSC engineering and systemic non‑viral LNP in vivo delivery.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Integra Therapeutics.
